For Biogen, an expensive gamble has paid off, as even with accelerated approval the company stands to make billions of dollars from aducanumab, given it estimates there are around 1.5 million ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Aducanumab – which Biogen is developing with Japanese drugmaker Eisai – was all but abandoned in 2019 after the partners decided that two phase 3 trials of the drug were unlikely to show an ...

Biogen's stock dove initially - erasing $18 billion in market value - after the discontinatuon in March, but then shot up by more than one-third in October. Markets Insider Now, aducanumab is set ...

Biogen says it will soon seek regulatory approval in the US for the "groundbreaking" drug, called aducanumab. It plans to file the paperwork in early 2020 and has its sights on Europe too.

If approved, Biogen’s aducanumab would be the first treatment designed to delay progression of the fatal, memory-robbing disease. The drug has had a tumultuous journey, with promising early data ...

America’s Food and Drug Administration (FDA) had just approved Biogen’s Aducanumab, the first drug for Alzheimer’s disease to be admitted to the market for 18 years. The US Alzheimer’s ...

She added: "Biogen must continue collecting essential data to clarify the safety and effectiveness of aducanumab. "While further data collection is happening in the US, the UK is uniquely well ...

Biogen's phase 3 Alzheimer's program for aducanumab was halted in March 2019 and produced mixed data. While the drug was approved in the US in June 2021, it has been a commercial failure.

Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in ...

Last month, when the biotech Biogen yanked a once-promising experimental Alzheimer's disease drug, it sent a ripple across the scientific and financial worlds. The drug, aducanumab, had been ...

The drugs, aducanumab (Aduhelm) and lecanemab (Leqembi), were approved in June 2021 and January 2023, respectively. Both drugs were developed by pharmaceutical companies Biogen and Eisai, and they ...